Hudock Inc’s Vertex Pharmaceuticals VRTX Stock Holding History

Hudock Inc’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$226K	Sell	433 -37	-8%	-$18.9K	0.03%	209
2026 Q2	$233K	Buy	+470	New	+$208K	0.03%	199
2022 Q4	–	Sell	-164	Closed	-$47K	–	737
2022 Q3	$47K	Hold	164	–	–	0.02%	318
2022 Q2	$46K	Hold	164	–	–	0.02%	317
2022 Q1	$42K	Hold	164	–	–	0.01%	341
2021 Q4	$36K	Hold	164	–	–	0.01%	364
2021 Q3	$29K	Buy	164 +100	+156%	+$19.5K	0.01%	401
2021 Q2	$12K	Hold	64	–	–	﹤0.01%	518
2021 Q1	$13K	Hold	64	–	–	﹤0.01%	502
2020 Q4	$15K	Sell	64 -10	-14%	-$2.29K	﹤0.01%	464
2020 Q3	$20K	Hold	74	–	–	0.01%	382
2020 Q2	$21K	Hold	74	–	–	0.01%	367
2020 Q1	$17K	Buy	+74	New	+$17K	0.01%	353

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return

IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

Hudock Inc's VRTX Position: Q3 2026 in Review

Hudock Inc reduced its Vertex Pharmaceuticals (VRTX) stake by 7.9% in Q3 2026, selling an estimated $18.9K and leaving 433 shares worth $226K. The position accounts for 0.03% of the portfolio, ranked #209.

Hudock Inc first reported a position in VRTX in Q1 2020 and has held it in 13 quarters since. The position peaked at $233K in Q2 2026. 299 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Hudock Inc held 433 shares of Vertex Pharmaceuticals worth $226K as of Q3 2026.
Hudock Inc sold 37 Vertex Pharmaceuticals shares in Q3 2026, an estimated $18.9K.
Vertex Pharmaceuticals made up 0.03% of Hudock Inc's portfolio in Q3 2026, its #209 holding.
Hudock Inc first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 13 quarters since.
Hudock Inc's Vertex Pharmaceuticals position peaked at $233K in Q2 2026.
299 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Hudock Inc's 13F filing for Q3 2026, filed 14 Oct 2026.